Increased protein insolubility in brains from a subset of patients with schizophrenia

Leslie Nucifora, Matthew L. MacDonald, Brian J. Lee, Matthew Peters, Alexis L. Norris, Benjamin C. Orsburn, Kun Yang, Kelly Gleason, Russell Louis Margolis, Jonathan A. Pevsner, Carol A. Tamminga, Robert A. Sweet, Christopher A Ross, Akira Sawa, Frederick Nucifora

Research output: Contribution to journalArticle

Abstract

Objective: The mechanisms leading to schizophrenia are likely to be diverse. However, there may be common pathophysiological pathways for subtypes of the disease. The authors tested the hypothesis that increased protein insolubility and ubiquitination underlie the pathophysiology for a subtype of schizophrenia. Methods: Prefrontal cortex and superior temporal gyrus from postmortem brains of individuals with and without schizophrenia were subjected to cold sarkosyl fractionation, separating proteins into soluble and insoluble fractions. Protein insolubility and ubiquitin levels were quantified for each insoluble fraction, with normalization to total homogenate protein. Mass spectrometry analysis was then performed to identify the protein contents of the insoluble fractions. The potential biological relevance of the detected proteins was assessed using Gene Ontology enrichment analysis and Ingenuity Pathway Analysis. Results: A subset of the schizophrenia brains showed an increase in protein insolubility and ubiquitination in the insoluble fraction. Mass spectrometry of the insoluble fraction revealed that brains with increased insolubility and ubiquitination exhibited a similar peptide expression by principal component analysis. The proteins that were significantly altered in the insoluble fraction were enriched for pathways relating to axon target recognition as well as nervous system development and function. Conclusions: This study suggests a pathological process related to protein insolubility for a subset of patients with schizophrenia. Determining the molecular mechanism of this subtype of schizophrenia could lead to a better understanding of the pathways underlying the clinical phenotype in some patients with major mental illness as well as to improved nosology and identification of novel therapeutic targets.

Original languageEnglish (US)
Pages (from-to)730-743
Number of pages14
JournalAmerican Journal of Psychiatry
Volume176
Issue number9
DOIs
StatePublished - Jan 1 2019

Fingerprint

Schizophrenia
Brain
Proteins
Ubiquitination
Mass Spectrometry
Gene Ontology
Critical Pathways
Pathologic Processes
Temporal Lobe
Ubiquitin
Principal Component Analysis
Prefrontal Cortex
Nervous System
Axons
Phenotype
Peptides

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Increased protein insolubility in brains from a subset of patients with schizophrenia. / Nucifora, Leslie; MacDonald, Matthew L.; Lee, Brian J.; Peters, Matthew; Norris, Alexis L.; Orsburn, Benjamin C.; Yang, Kun; Gleason, Kelly; Margolis, Russell Louis; Pevsner, Jonathan A.; Tamminga, Carol A.; Sweet, Robert A.; Ross, Christopher A; Sawa, Akira; Nucifora, Frederick.

In: American Journal of Psychiatry, Vol. 176, No. 9, 01.01.2019, p. 730-743.

Research output: Contribution to journalArticle

@article{06f86f1ee85b43b28826faab52fbe2bb,
title = "Increased protein insolubility in brains from a subset of patients with schizophrenia",
abstract = "Objective: The mechanisms leading to schizophrenia are likely to be diverse. However, there may be common pathophysiological pathways for subtypes of the disease. The authors tested the hypothesis that increased protein insolubility and ubiquitination underlie the pathophysiology for a subtype of schizophrenia. Methods: Prefrontal cortex and superior temporal gyrus from postmortem brains of individuals with and without schizophrenia were subjected to cold sarkosyl fractionation, separating proteins into soluble and insoluble fractions. Protein insolubility and ubiquitin levels were quantified for each insoluble fraction, with normalization to total homogenate protein. Mass spectrometry analysis was then performed to identify the protein contents of the insoluble fractions. The potential biological relevance of the detected proteins was assessed using Gene Ontology enrichment analysis and Ingenuity Pathway Analysis. Results: A subset of the schizophrenia brains showed an increase in protein insolubility and ubiquitination in the insoluble fraction. Mass spectrometry of the insoluble fraction revealed that brains with increased insolubility and ubiquitination exhibited a similar peptide expression by principal component analysis. The proteins that were significantly altered in the insoluble fraction were enriched for pathways relating to axon target recognition as well as nervous system development and function. Conclusions: This study suggests a pathological process related to protein insolubility for a subset of patients with schizophrenia. Determining the molecular mechanism of this subtype of schizophrenia could lead to a better understanding of the pathways underlying the clinical phenotype in some patients with major mental illness as well as to improved nosology and identification of novel therapeutic targets.",
author = "Leslie Nucifora and MacDonald, {Matthew L.} and Lee, {Brian J.} and Matthew Peters and Norris, {Alexis L.} and Orsburn, {Benjamin C.} and Kun Yang and Kelly Gleason and Margolis, {Russell Louis} and Pevsner, {Jonathan A.} and Tamminga, {Carol A.} and Sweet, {Robert A.} and Ross, {Christopher A} and Akira Sawa and Frederick Nucifora",
year = "2019",
month = "1",
day = "1",
doi = "10.1176/appi.ajp.2019.18070864",
language = "English (US)",
volume = "176",
pages = "730--743",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "9",

}

TY - JOUR

T1 - Increased protein insolubility in brains from a subset of patients with schizophrenia

AU - Nucifora, Leslie

AU - MacDonald, Matthew L.

AU - Lee, Brian J.

AU - Peters, Matthew

AU - Norris, Alexis L.

AU - Orsburn, Benjamin C.

AU - Yang, Kun

AU - Gleason, Kelly

AU - Margolis, Russell Louis

AU - Pevsner, Jonathan A.

AU - Tamminga, Carol A.

AU - Sweet, Robert A.

AU - Ross, Christopher A

AU - Sawa, Akira

AU - Nucifora, Frederick

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: The mechanisms leading to schizophrenia are likely to be diverse. However, there may be common pathophysiological pathways for subtypes of the disease. The authors tested the hypothesis that increased protein insolubility and ubiquitination underlie the pathophysiology for a subtype of schizophrenia. Methods: Prefrontal cortex and superior temporal gyrus from postmortem brains of individuals with and without schizophrenia were subjected to cold sarkosyl fractionation, separating proteins into soluble and insoluble fractions. Protein insolubility and ubiquitin levels were quantified for each insoluble fraction, with normalization to total homogenate protein. Mass spectrometry analysis was then performed to identify the protein contents of the insoluble fractions. The potential biological relevance of the detected proteins was assessed using Gene Ontology enrichment analysis and Ingenuity Pathway Analysis. Results: A subset of the schizophrenia brains showed an increase in protein insolubility and ubiquitination in the insoluble fraction. Mass spectrometry of the insoluble fraction revealed that brains with increased insolubility and ubiquitination exhibited a similar peptide expression by principal component analysis. The proteins that were significantly altered in the insoluble fraction were enriched for pathways relating to axon target recognition as well as nervous system development and function. Conclusions: This study suggests a pathological process related to protein insolubility for a subset of patients with schizophrenia. Determining the molecular mechanism of this subtype of schizophrenia could lead to a better understanding of the pathways underlying the clinical phenotype in some patients with major mental illness as well as to improved nosology and identification of novel therapeutic targets.

AB - Objective: The mechanisms leading to schizophrenia are likely to be diverse. However, there may be common pathophysiological pathways for subtypes of the disease. The authors tested the hypothesis that increased protein insolubility and ubiquitination underlie the pathophysiology for a subtype of schizophrenia. Methods: Prefrontal cortex and superior temporal gyrus from postmortem brains of individuals with and without schizophrenia were subjected to cold sarkosyl fractionation, separating proteins into soluble and insoluble fractions. Protein insolubility and ubiquitin levels were quantified for each insoluble fraction, with normalization to total homogenate protein. Mass spectrometry analysis was then performed to identify the protein contents of the insoluble fractions. The potential biological relevance of the detected proteins was assessed using Gene Ontology enrichment analysis and Ingenuity Pathway Analysis. Results: A subset of the schizophrenia brains showed an increase in protein insolubility and ubiquitination in the insoluble fraction. Mass spectrometry of the insoluble fraction revealed that brains with increased insolubility and ubiquitination exhibited a similar peptide expression by principal component analysis. The proteins that were significantly altered in the insoluble fraction were enriched for pathways relating to axon target recognition as well as nervous system development and function. Conclusions: This study suggests a pathological process related to protein insolubility for a subset of patients with schizophrenia. Determining the molecular mechanism of this subtype of schizophrenia could lead to a better understanding of the pathways underlying the clinical phenotype in some patients with major mental illness as well as to improved nosology and identification of novel therapeutic targets.

UR - http://www.scopus.com/inward/record.url?scp=85071782838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071782838&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2019.18070864

DO - 10.1176/appi.ajp.2019.18070864

M3 - Article

C2 - 31055969

AN - SCOPUS:85071782838

VL - 176

SP - 730

EP - 743

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 9

ER -